Barclays raised the firm’s price target on Cigna (CI) to $420 from $405 and keeps an Overweight rating on the shares after its Q3 earnings beat last week. After the company’s solid quarter and an encouraging 2025 preliminary outlook, Cigna has also emphasized a continued focus on share repurchase through year-end, including $715M in October, and reiterated that the majority of proceeds relates to the $3.7B sale of its Medicare business would be used for share repurchase, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target lowered to $394 from $398 at Deutsche Bank
- Cigna price target lowered to $391 from $400 at TD Cowen
- Cigna Healthcare, Infirmary Health reach Medicare Advantage agreement
- Cigna Reports Strong Q3 2024 Results with Revenue Surge
- Morning Movers: Roblox surges and Estee Lauder sinks following earnings